Medicure Company Profile (CVE:MPH)

About Medicure

Medicure logoMedicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: CVE
  • Symbol: MPH
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • 52-Week Range: C$3.00 - C$7.29
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
  • Market Cap: $N/A
  • Outstanding Shares: 15,019,000
Additional Links:

Analyst Ratings

Consensus Ratings for Medicure (CVE:MPH) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: C$8.00

Analysts' Ratings History for Medicure (CVE:MPH)
DateFirmActionRatingPrice TargetDetails
5/4/2016M PartnersReiterated RatingBuyView Rating Details
1/12/2016MackieBoost Price TargetBuyC$8.00View Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Medicure (CVE:MPH)
No earnings announcements for this company have been tracked by


Earnings Estimates for Medicure (CVE:MPH)
Current Year EPS Consensus Estimate: $0.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.13$0.13$0.13
Q2 20161$0.13$0.13$0.13
Q3 20161$0.16$0.16$0.16
Q4 20161$0.18$0.18$0.18
Q1 20171$0.26$0.26$0.26
Q2 20171$0.27$0.27$0.27
Q3 20171$0.29$0.29$0.29
Q4 20171$0.31$0.31$0.31
(Data provided by Zacks Investment Research)


Dividend History for Medicure (CVE:MPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Medicure (CVE:MPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/17/2016Albert David FriesenDirectorBuy1,100C$5.55C$6,105.00
3/16/2016Graeme William MerchantInsiderBuy1,650C$6.40C$10,560.00
3/11/2016Graeme William MerchantInsiderBuy1,500C$6.30C$9,450.00
3/8/2016Graeme William MerchantInsiderSell6,300C$7.01C$44,163.00
9/9/2015Elliott International CapitalInsiderSell1,426,002C$2.98C$4,249,485.96
1/7/2015Albert David FriesenDirectorBuy2,900C$2.01C$5,829.00
(Data available from 1/1/2013 forward)


Latest Headlines for Medicure (CVE:MPH)
DateHeadline logoReminder - InterRent Real Estate Investment Trust (IIP-UN) Goes Ex-Dividend Soon (CVE:MPH) - September 27 at 10:49 AM logoNew AGGRASTAT® Product Format Gains FDA Approval (CVE:MPH) - September 1 at 6:09 PM
News IconMedicure Release: FDA Approves New AGGRASTAT Product Format (CVE:MPH) - September 1 at 6:09 PM logoMedicure Reports Second Quarter 2016 Financial Results (CVE:MPH) - August 11 at 9:26 AM logoMedicure Inc. (MPH.V) (CVE:MPH) - February 24 at 10:28 AM logoUndervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap (CVE:MPH) - February 17 at 10:03 AM logoMedicure To Present At Cantech Investment Conference (CVE:MPH) - January 22 at 9:43 AM logoMedicure Inc V.MPH.H (CVE:MPH) - January 17 at 9:01 AM


Medicure (CVE:MPH) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff